2025
SJR Q1
JCR Q1 · 6,4
12 eşleşen makale
SCIE
Dergi ayrıntısı
Cancer Gene Therapy
- Yayıncı
- Springer Nature
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0929190314765500
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,749
- Quartile Q1
- H-Index 103
- Atıf/yayın 6,07
- Doküman (3y) 488
- Atıf (3y) 2.829
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 6,4
- 5Y JIF 5,9
- JCI 1,11
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Cancer Research Q2
- Molecular Biology Q1
- Molecular Medicine Q1
Alanlar
- Biochemistry, Genetics and Molecular Biology
WoS kategorileri
- Biotechnology & Applied Microbiology | Oncology | Genetics & Heredity | Medicine, Research & Experimental
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,749 | 6,4 | 5,9 | 1,11 | Q1 | 103 |
| 2024 | Q1 | Q1 | 1,727 | 5 | 5,2 | 1,07 | Q1 | 101 |
| 2023 | Q1 | Q1 | 1,457 | 4,8 | 4,9 | 1,1 | Q1 | 101 |
| 2022 | Q1 | Q1 | 1,384 | 6,4 | 6,1 | 1,24 | Q1 | 101 |
| 2021 | Q2 | Q1 | 1,207 | 5,9 | 5,7 | 1,28 | Q1 | 101 |
| 2020 | Q1 | Q1 | 1,535 | 6 | 5,4 | 1,26 | Q1 | 101 |
| 2019 | Q2 | Q1 | 0,93 | 4,5 | 4 | 1,21 | Q1 | 101 |
| 2018 | — | Q1 | — | 4,7 | 3,3 | 1,14 | Q1 | — |
| 2017 | Q2 | Q1 | 1,359 | 4 | 3 | 1,01 | Q1 | 101 |
| 2016 | Q2 | Q1 | 1,098 | 3,7 | 2,8 | — | — | 101 |
| 2015 | Q2 | Q2 | 1,014 | 2,5 | 2,3 | — | — | 101 |
| 2014 | Q3 | Q2 | 0,93 | 2,4 | 2,3 | — | — | 101 |
| 2013 | Q2 | Q2 | 1,072 | 2,6 | 2,6 | — | — | 101 |
| 2012 | Q2 | Q2 | 1,171 | 2,9 | 2,8 | — | — | 101 |
| 2011 | Q2 | Q2 | 1,309 | 2,8 | 2,5 | — | — | 101 |
| 2010 | Q2 | Q1 | 1,327 | 3,7 | 3,4 | — | — | 101 |
| 2009 | — | Q2 | — | 3,1 | 3 | — | — | — |
| 2008 | — | Q1 | — | 3 | 2,9 | — | — | — |
| 2007 | — | Q1 | — | 3,9 | 3,3 | — | — | — |
| 2006 | — | Q1 | — | 4,2 | — | — | — | — |
| 2005 | — | Q1 | — | 3 | — | — | — | — |
| 2004 | — | Q1 | — | 3,7 | — | — | — | — |
| 2003 | — | Q1 | — | 3,7 | — | — | — | — |
| 2002 | — | Q1 | — | 2,9 | — | — | — | — |
| 2001 | — | Q1 | — | 2,8 | — | — | — | — |
| 2000 | — | Q1 | — | 4,2 | — | — | — | — |
| 1999 | — | Q1 | — | 4,2 | — | — | — | — |
| 1998 | — | Q1 | — | 4,3 | — | — | — | — |
| 1997 | — | Q1 | — | 3,7 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 27/180 |
| 2025 | GENETICS & HEREDITY | SCIE | Q1 | Q1 | 21/192 |
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 39/191 |
| 2025 | ONCOLOGY | SCIE | Q1 | Q1 | 59/333 |
| 2024 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 27/177 |
| 2024 | GENETICS & HEREDITY | SCIE | Q1 | Q1 | 27/192 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 45/195 |
| 2024 | ONCOLOGY | SCIE | Q1 | Q1 | 71/328 |
| 2023 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 27/174 |
| 2023 | GENETICS & HEREDITY | SCIE | Q1 | Q1 | 29/191 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 45/189 |
| 2023 | ONCOLOGY | SCIE | Q1 | Q1 | 70/322 |
| 2022 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 20/158 |
| 2022 | GENETICS & HEREDITY | SCIE | Q1 | Q1 | 22/171 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 31/136 |
| 2022 | ONCOLOGY | SCIE | Q1 | Q1 | 52/241 |
| 2021 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 32/159 |
| 2021 | GENETICS & HEREDITY | SCIE | Q1 | Q1 | 30/175 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q1 | 42/139 |
| 2021 | ONCOLOGY | SCIE | Q2 | Q1 | 74/245 |
| 2020 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 21/159 |
| 2020 | GENETICS & HEREDITY | SCIE | Q1 | Q1 | 26/176 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 34/140 |
| 2020 | ONCOLOGY | SCIE | Q2 | Q1 | 66/242 |
| 2019 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 25/156 |
| 2019 | GENETICS & HEREDITY | SCIE | Q1 | Q1 | 33/178 |
| 2019 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 33/139 |
| 2019 | ONCOLOGY | SCIE | Q2 | Q1 | 78/244 |
| 2018 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 24/162 |
| 2018 | GENETICS & HEREDITY | SCIE | Q1 | Q1 | 30/174 |
| 2018 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q1 | 29/136 |
| 2018 | ONCOLOGY | SCIE | Q2 | Q1 | 59/230 |
| 2017 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | Q1 | 28/161 |
| 2017 | GENETICS & HEREDITY | SCIE | Q1 | Q2 | 40/171 |
| 2017 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 31/133 |
| 2017 | ONCOLOGY | SCIE | Q2 | Q2 | 70/223 |
| 2016 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 40/160 |
| 2016 | GENETICS & HEREDITY | SCIE | Q2 | — | 53/167 |
| 2016 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 33/128 |
| 2016 | ONCOLOGY | SCIE | Q2 | — | 80/217 |
| 2015 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 59/161 |
| 2015 | GENETICS & HEREDITY | SCIE | Q2 | — | 82/166 |
| 2015 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 58/124 |
| 2015 | ONCOLOGY | SCIE | Q3 | — | 128/213 |
| 2014 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 67/163 |
| 2014 | GENETICS & HEREDITY | SCIE | Q3 | — | 89/167 |
| 2014 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 64/123 |
| 2014 | ONCOLOGY | SCIE | Q3 | — | 127/211 |
| 2013 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 58/165 |
| 2013 | GENETICS & HEREDITY | SCIE | Q3 | — | 85/165 |
| 2013 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 52/124 |
| 2013 | ONCOLOGY | SCIE | Q3 | — | 116/203 |
| 2012 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 49/160 |
| 2012 | GENETICS & HEREDITY | SCIE | Q2 | — | 67/161 |
| 2012 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 44/121 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 82/197 |
| 2011 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 53/158 |
| 2011 | GENETICS & HEREDITY | SCIE | Q2 | — | 70/158 |
| 2011 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 42/112 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 85/196 |
| 2010 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 33/160 |
| 2010 | GENETICS & HEREDITY | SCIE | Q2 | — | 48/156 |
| 2010 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 23/106 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 56/185 |
| 2009 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q2 | — | 43/152 |
| 2009 | GENETICS & HEREDITY | SCIE | Q2 | — | 59/146 |
| 2009 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 26/93 |
| 2009 | ONCOLOGY | SCIE | Q2 | — | 63/166 |
| 2008 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 36/144 |
| 2008 | GENETICS & HEREDITY | SCIE | Q2 | — | 59/138 |
| 2008 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 24/83 |
| 2008 | ONCOLOGY | SCIE | Q2 | — | 60/143 |
| 2007 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 24/138 |
| 2007 | GENETICS & HEREDITY | SCIE | Q2 | — | 45/132 |
| 2007 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 16/81 |
| 2007 | ONCOLOGY | SCIE | Q2 | — | 42/132 |
| 2006 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 17/140 |
| 2006 | GENETICS & HEREDITY | SCIE | Q2 | — | 33/131 |
| 2006 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 13/76 |
| 2006 | ONCOLOGY | SCIE | Q2 | — | 37/127 |
| 2005 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 30/139 |
| 2005 | GENETICS & HEREDITY | SCIE | Q2 | — | 54/124 |
| 2005 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 16/72 |
| 2005 | ONCOLOGY | SCIE | Q2 | — | 51/123 |
| 2004 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 19/133 |
| 2004 | GENETICS & HEREDITY | SCIE | Q2 | — | 36/120 |
| 2004 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 12/71 |
| 2004 | ONCOLOGY | SCIE | Q2 | — | 34/123 |
| 2003 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 17/132 |
| 2003 | GENETICS & HEREDITY | SCIE | Q2 | — | 31/120 |
| 2003 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 13/72 |
| 2003 | ONCOLOGY | SCIE | Q1 | — | 30/120 |
| 2002 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 23/131 |
| 2002 | GENETICS & HEREDITY | SCIE | Q2 | — | 42/115 |
| 2002 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 15/74 |
| 2002 | ONCOLOGY | SCIE | Q2 | — | 32/114 |
| 2001 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 21/131 |
| 2001 | GENETICS & HEREDITY | SCIE | Q2 | — | 45/113 |
| 2001 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 16/75 |
| 2001 | ONCOLOGY | SCIE | Q2 | — | 36/107 |
| 2000 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 10/134 |
| 2000 | GENETICS & HEREDITY | SCIE | Q1 | — | 21/114 |
| 2000 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 8/74 |
| 2000 | ONCOLOGY | SCIE | Q1 | — | 11/103 |
| 1999 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 10/124 |
| 1999 | GENETICS & HEREDITY | SCIE | Q1 | — | 20/105 |
| 1999 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 8/76 |
| 1999 | ONCOLOGY | SCIE | Q1 | — | 9/105 |
| 1998 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 9/123 |
| 1998 | GENETICS & HEREDITY | SCIE | Q1 | — | 16/103 |
| 1998 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 8/72 |
| 1998 | ONCOLOGY | SCIE | Q1 | — | 8/104 |
| 1997 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q1 | — | 8/94 |
| 1997 | GENETICS & HEREDITY | SCIE | Q1 | — | 18/90 |
| 1997 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 9/61 |
| 1997 | ONCOLOGY | SCIE | Q1 | — | 10/102 |